Locations:
Search IconSearch
May 16, 2017/Cancer/News & Insight

Brian Bolwell, MD, on Priorities, Leadership in Evolving Healthcare Environment

Cancer Center Chairman discusses leading through change

bolwell_650x450

Dr. Bolwell is Chair of Physician Leadership and Development and former Chair of Taussig Cancer Institute. He can be reached at bolwelb@ccf.org or 216.444.6922. On Twitter: @BrianBolwellMD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Q: The U.S. Department of Health and Human Services Agency for Healthcare Research and Quality has over 2000 metrics for clinical quality. How do you address so many metrics at one time?

A: When you sit in front of a patient and try to help them, it’s hard to imagine there are actually 2000 things to measure. But I do think many of the metrics make sense, especially those dealing with quality, like the incidence of deep venous thrombosis after surgery.

As a leader, I focus on how to get a team of people to go from point A to point B. I think if you tell a team they need to meet 55 different metric goals that tends to be rather overwhelming. There’s a finite number of things on which I can ask them to focus, and if we do those very well, it’s likely that many other things will follow.

I think of the analogy of a golf swing. It’s actually very difficult to swing well. I remember someone telling me years ago that if you finish a swing in balance and you’re pointing to the target you’ve probably made a pretty good swing. Similarly, I think if we can focus on a handful of things and do them well, it’s pretty likely that we’re doing a whole bunch of other things well, too.

Q: What metrics does Cleveland Clinic Cancer Center prioritize and why?

A: We focus on three priorities that I think are fundamental. Quality and safety is number one. Number two is treating people well, and number three is access.

You have to lead with quality and safety. Very early in my career, I was running the bone marrow transplant program, and we heard about a couple of catastrophic events that happened at another center in which patients received fatal doses of chemotherapy. It turned that organization on its head, and it certainly changed the way we order chemotherapy here. When I began leading this center, our goal was to eliminate harm events from chemotherapy, and by working together with our nursing colleagues, we’ve actually lowered our chemotherapy harm events to zero for the past five years.

Advertisement

The second thing is treating people well, and that starts with our own work family. I think if we ensure that everyone in our work environment is treating the entire team with respect, then it’s highly likely we’ll treat patients and their families well.

Finally, we are incredibly focused on access. I think the time it takes for a person to receive their first therapy after diagnosis is a surrogate marker for the amount of empathy in a culture. It’s a cultural thing. People need to be seen; we get them in and see them. We know they’re anxious and scared and respect that with prompt access. I’m happy with the progress we’ve made on time to treat metrics thus far. I think improving access cascades to many other measures.

Q: Reimbursement tied to specific metrics is just one example of the tumultuous changes occurring in healthcare in general and in oncology in particular. As a leader, how do you promote the well-being of your colleagues in such an environment?

A: The whole field of oncology is changing very, very rapidly. I think that for most of us, simply keeping up is a challenge. I think step one is to communicate with staff. Be transparent about what is going on in the organization and outside of the organization. People need to know why we’re being asked to do whatever the task at hand might be.

Another focus is teamwork. I think the shift to value-based care has caused disruptive change, but the emphasis on integrated teams has been a particularly helpful change. That’s the whole key to value-based care. But by nature, most physicians are pretty independent. Teamwork was not a qualification to get into medical school or residency, and it’s not something with which everyone is comfortable.

Advertisement

Our care paths are a good example of a response to value-based care that has fostered teamwork. To analyze what treatments work best, what should be the standard of care, we involved team members from different institutes, different locations, in different positions. The goal was to adopt a standard of care, but we also created a sense of teamwork that fosters collaboration and gets people working together on a task, which is important to creating an environment in which people feel comfortable and fulfilled in their daily work.

Q: What enables you to lead through this time of change?

A: A while ago I was fortunate to undergo formal leadership training, which included an extensive report of my colleagues’ perceptions of me and my leadership style. It was basically a 20-page report in which they told me everything I did wrong, but it was incredibly useful. Openness to constructive criticism is key. It was eye opening; I learned and changed a lot.

I’ve read about 40 books on the topic of leadership, and I’ve gravitated to something called serving leadership, which just makes sense to me. It means that I have three goals: set a clear vision, which is harder than it sounds. Hire wonderful people and enable them to succeed. And then remove the barriers. I think that’s a big part of how I can contribute to the team’s well-being. Anytime you work in a large organization there are barriers, political or otherwise. My job is to remove those and let people do their jobs.

As a leader, if I can focus on those three things, and if as a Cancer Center, we can focus on quality and safety, respect for one another and access, then no matter how the external environment demands change, we will succeed.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad